These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 33314628)

  • 1. Nanotechnology-based approaches for treating lysosomal storage disorders, a focus on Fabry disease.
    Abasolo I; Seras-Franzoso J; Moltó-Abad M; Díaz-Riascos V; Corchero JL; Pintos-Morell G; Schwartz S
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2021 May; 13(3):e1684. PubMed ID: 33314628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiac involvement in Lysosomal Storage Diseases.
    Sestito S; Parisi F; Tallarico V; Tarsitano F; Roppa K; Pensabene L; Chimenz R; Ceravolo G; Calabrò MP; De Sarro R; Moricca MT; Bonapace G; Concolino D
    J Biol Regul Homeost Agents; 2020; 34(4 Suppl. 2):107-119. SPECIAL ISSUE: FOCUS ON PEDIATRIC CARDIOLOGY. PubMed ID: 33000609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treating lysosomal storage disorders: What have we learnt?
    Lachmann RH
    J Inherit Metab Dis; 2020 Jan; 43(1):125-132. PubMed ID: 31140601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic Role of Pharmacological Chaperones in Lysosomal Storage Disorders: A Review of the Evidence and Informed Approach to Reclassification.
    Keyzor I; Shohet S; Castelli J; Sitaraman S; Veleva-Rotse B; Weimer JM; Fox B; Willer T; Tuske S; Crathorne L; Belzar KJ
    Biomolecules; 2023 Aug; 13(8):. PubMed ID: 37627292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current treatment options and novel nanotechnology-driven enzyme replacement strategies for lysosomal storage disorders.
    Del Grosso A; Parlanti G; Mezzena R; Cecchini M
    Adv Drug Deliv Rev; 2022 Sep; 188():114464. PubMed ID: 35878795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extracellular vesicles from recombinant cell factories improve the activity and efficacy of enzymes defective in lysosomal storage disorders.
    Seras-Franzoso J; Díaz-Riascos ZV; Corchero JL; González P; García-Aranda N; Mandaña M; Riera R; Boullosa A; Mancilla S; Grayston A; Moltó-Abad M; Garcia-Fruitós E; Mendoza R; Pintos-Morell G; Albertazzi L; Rosell A; Casas J; Villaverde A; Schwartz S; Abasolo I
    J Extracell Vesicles; 2021 Mar; 10(5):e12058. PubMed ID: 33738082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A polylysine-polyhistidine fusion peptide for lysosome-targeted protein delivery.
    Iwasaki T; Murakami N; Kawano T
    Biochem Biophys Res Commun; 2020 Dec; 533(4):905-912. PubMed ID: 33008588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enzyme replacement therapy for lysosomal storage diseases.
    Ohashi T
    Pediatr Endocrinol Rev; 2012 Oct; 10 Suppl 1():26-34. PubMed ID: 23330243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of lysosomal storage diseases: recent patents and future strategies.
    Ortolano S; Viéitez I; Navarro C; Spuch C
    Recent Pat Endocr Metab Immune Drug Discov; 2014 Jan; 8(1):9-25. PubMed ID: 24433521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics.
    Parenti G
    EMBO Mol Med; 2009 Aug; 1(5):268-79. PubMed ID: 20049730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Highly Versatile Polyelectrolyte Complexes for Improving the Enzyme Replacement Therapy of Lysosomal Storage Disorders.
    Giannotti MI; Abasolo I; Oliva M; Andrade F; García-Aranda N; Melgarejo M; Pulido D; Corchero JL; Fernández Y; Villaverde A; Royo M; García-Parajo MF; Sanz F; Schwartz S
    ACS Appl Mater Interfaces; 2016 Oct; 8(39):25741-25752. PubMed ID: 27610822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exosome- and extracellular vesicle-based approaches for the treatment of lysosomal storage disorders.
    Lu B; Ku J; Flojo R; Olson C; Bengford D; Marriott G
    Adv Drug Deliv Rev; 2022 Sep; 188():114465. PubMed ID: 35878794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effectiveness and cost-effectiveness of enzyme and substrate replacement therapies: a longitudinal cohort study of people with lysosomal storage disorders.
    Wyatt K; Henley W; Anderson L; Anderson R; Nikolaou V; Stein K; Klinger L; Hughes D; Waldek S; Lachmann R; Mehta A; Vellodi A; Logan S
    Health Technol Assess; 2012; 16(39):1-543. PubMed ID: 23089251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impaired autophagic and mitochondrial functions are partially restored by ERT in Gaucher and Fabry diseases.
    Ivanova MM; Changsila E; Iaonou C; Goker-Alpan O
    PLoS One; 2019; 14(1):e0210617. PubMed ID: 30633777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Enzyme replacement therapy of lysosomal storage diseases].
    Germain DP; Boucly C; Carlier RY; Caudron E; Charlier P; Colas F; Jabbour F; Martinez V; Mokhtari S; Orlikowski D; Pellegrini N; Perronne C; Prigent H; Rubinsztajn R; Benistan K
    Rev Med Interne; 2010 Dec; 31 Suppl 2():S279-91. PubMed ID: 21211680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Virus-like nanoparticles as enzyme carriers for Enzyme Replacement Therapy (ERT).
    González-Davis O; Villagrana-Escareño MV; Trujillo MA; Gama P; Chauhan K; Vazquez-Duhalt R
    Virology; 2023 Mar; 580():73-87. PubMed ID: 36791560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enzyme Replacement Therapy: A Review and Its Role in Treating Lysosomal Storage Diseases.
    Li M
    Pediatr Ann; 2018 May; 47(5):e191-e197. PubMed ID: 29750286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Enzyme replacement therapy for lysosomal storage disorders].
    Valayannopoulos V; Brassier A; Chabli A; Caillaud C; Lemoine M; Odent T; Arnoux JB; de Lonlay P
    Arch Pediatr; 2011 Oct; 18(10):1119-23. PubMed ID: 21873040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A charitable access program for patients with lysosomal storage disorders in underserved communities worldwide.
    Mehta A; Ramaswami U; Muenzer J; Giugliani R; Ullrich K; Collin-Histed T; Panahloo Z; Wellhoefer H; Frader J
    Orphanet J Rare Dis; 2021 Jan; 16(1):8. PubMed ID: 33407729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enzyme enhancement therapeutics for lysosomal storage diseases: Current status and perspective.
    Thomas R; Kermode AR
    Mol Genet Metab; 2019 Feb; 126(2):83-97. PubMed ID: 30528228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.